Skip to Content
  • Silicon Valley Sunglasses

    The intersection between Silicon-Valley-style tech and biotech is getting a lot of attention these days. Some of it looks like it could be a productive synthesi… Read More
  • Taking Your Doses For You

    MIT’s Bob Langer has another idea: he’s looking to change the way that entire courses of treatment are dosed. What if an extended-release formulatio… Read More
  • Tone It Down

    You know, I’m not sure I should have cut Atomwise so much slack the other day. I just came across this piece on them, and. . .well, I’ll let it spea… Read More
  • Transcelerate Status Report

    Here’s a followup to something I wrote in 2012. That was when a joint venture called Trancelerate was announced to address precompetitive drug development… Read More
  • Drug Development for Academics

    I have a book review out in Nature Chemical Biology of A Practical Guide to Drug Development in Academia. As you’ll see, I liked it, finding it a very use… Read More
  • Optimistic Stem Cell Quotes

    How does the press cover stem cell work? You probably already know the answer to that one, but here’s proof: this paper examines the media coverage from 2… Read More
  • 23AndMe

    Now this is quite a development: 23andMe is the personal genomics company that had a run-in with the FDA and is still trying to come to terms with the agency ov… Read More
  • Twenty-One Billion Dollars. Really.

    Ibrutinib seems to be worth even more than everyone thought! As of this morning, AbbVie has won what was apparently a lively bidding war for Pharmacyclics, payi… Read More
  • Of Proteasome Inhibitors and PAINs

    Amgen is out with some new data that might well justify their purchase of Onyx a year and a half ago. A big driver for that deal was the proteasome inhibitor Ky… Read More
Page 10 of 54« First...89101112...203040...Last »